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Abstract
Background. Hyperglycemia exacerbates focal ischemic brain damage supposedly through various mechanisms. One such
mechanism is oxidative stress involving reactive oxygen and nitrogen species (RONS) production. Nitrones attenuate oxidative
stress in various models of brain injury. Sodium 2-sulfophenyl-N-tert-butyl nitrone (S-PBN) can be administered exper-
imentally and has been shown to be neuroprotective in experimental brain trauma.
Aims of the study. We hypothesized that S-PBN might be neuroprotective in hyperglycemic focal cerebral ischemia.
Material and methods. Rats were made hyperglycemic by an intraperitoneal bolus injection of glucose (2 g/kg) and then
subjected to 90 min transient middle cerebral artery occlusion (MCAO). They were randomized to a therapeutic regime of
S-PBN (156 mg/kg) or saline given intravenously. Neurological testing according to Bederson and tetrazolium red staining
were performed after 1 day.
Results. S-PBN improved the neurological performance at day 1 both in Bederson score (1.3 ± 0.8 versus 2.7 ± 0.48) and on the
inclined plane (74.5% ± 4.6 (S-PBN) versus 66% ± 8.3 (control), P < 0.05) but did not reduce the infarct size. Physiological
data did not differ between groups.
Conclusion. S-PBN may improve neurological performance at short-term survival (1 day) in the present model of
hyperglycemic-ischemic brain injury in rats. This effect appeared not to be primarily related to reduced infarct size.
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Introduction
Ischemic stroke is a common and life-threatening
neurological disease with substantial morbidity and
mortality. Coexisting hyperglycemia occurs in a
majority of stroke patients (1) and further aggravates
the ischemic brain injury, an observation supported
by experimental (2) and clinical studies (3).
The pathogenesis for neuronal damage following
ischemic insult includes multiple mechanisms rang-
ing from anaerobic metabolism with lactic acidosis to
altered cell signaling, and all have been implicated in
experimental studies (4,5). Data from our studies and
other laboratories demonstrate that ischemia with
concomitant hyperglycemia exaggerates the activation
of extracellular signal-regulated kinase (ERK) (2,5),
which in turn can be activated by intermediates of
reactive oxygen and nitrogen species (RONS) (6).
RONS play an important role in the pathology of
cerebral ischemia and therefore have been targeted
with the spin-trapping agent a-phenyl-N-tert-butyl
nitrone (PBN), whose therapeutic potential has
been reported in multiple studies of ischemic brain
injury (7,8). In a previous report from our laboratory
it was found that PBN reduced the hyperglycemic-
ischemic damage in rats (9).
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nated (S-) nitrones such as S-PBN and the dual-
sulfonated NXY-059. S-PBN attenuates the oxidative
stress in traumatic brain injury (10), and NXY-059
has shown neuroprotective properties in a primate
model of permanent ischemia (11), although clinical
results this far have been disappointing (12). Based on
promising data on PBN in hyperglycemic-ischemic
injury (9) and the compelling feasibility of sulfonated
nitrones in the treatment of ischemic brain damage,
we hypothesized S-PBN to be neuroprotective in focal
ischemia-reperfusion with concomitant hyperglyce-
mia in rats. To the best of our knowledge, such
experiments have not been previously reported.
Material and methods
MaleSprague-Dawleyratsweresubjectedtoleftmiddle
cerebral artery occlusion (MCAO), induced with the
ﬁlament technique (13) and maintained for 90 min
followed by a 1 day reperfusion. Anesthesia was in-
ducedbyanintraperitoneal(IP)injection(3mL/kg)ofa
4-folddilution offentanyl/ﬂuanisone (Hypnorm
  TM;
Janssen pharmaceutica; Beerse, Belgium) and midazo-
lam (Dormicum
 ; F. Hoffmann-La Roche AG, Basel,
Switzerland, 5 mg/mL) and was maintained with
doses of 0.9 mL/kg IP as needed. Prior to MCAO the
rats were given an IP glucose bolus injection (2 g/kg)
(14). The tail artery was catheterized for measurement
of mean arterial blood pressure and blood gas samp-
ling.APE-50catheterwasinsertedintotheleftfemoral
veinforintravenousaccess.Rectaltemperaturewaskept
at37.5C±0.5Cbyusingaheatinglamp.Thesurgical
procedure included exposure of the left carotid bifur-
cation, after which the small branches of the external
carotid artery (ECA) were divided and the pterygopa-
latine artery ligated. Then, a monoﬁlament (Ethilon
3/0;Ethicon,Cornelia,GA,USA)wasinsertedintothe
ECA and gently advanced through the internal carotid
arteryuntil a slight resistance was felt, indicating place-
mentattheoriginofthemiddlecerebralartery(MCA).
Electroencephalogram (EEG) was recorded over the
left MCA region in order to verify ischemia (9). The
rats were randomized to a therapeutic regime of a
sodium 2-sulfophenyl-N-tert-butyl nitrone (S-PBN,
156 mg/kg) (9) or saline (0.9% NaCl) given as a
60-min intravenous infusion starting after 60 min of
MCAO. The randomization was kept blinded to the
operator until the experiment was terminated. The
Uppsala Ethical Committee of Animal Research
(C69/5) approved this study.
After 1 day, muscular strength and proprioception
were examined using an inclined plane (15). The
maximal elevation angle was recorded as an average
of three attempts prior to surgery and after 1 day. In
addition, the neurological deﬁcit was scored using a
four-level scale (16), and the rats were graded as
normal (= 0), forelimb ﬂexion (= 1), decreased resis-
tance to lateral push (= 2), or circling (= 3).
The rats were then perfused using tri-phenyl-tetra-
zolium-chloride red (TTC, 2%) and phosphate-
buffered formaldehyde (4%, pH 7.4) in anesthesia
(17). The brains were removed and sectioned into
2-mm slices. Photographs were taken from the slices
for volumetric analysis, based on sections ranging
2–14 mm from the frontal brain pole. The lesions
were delineated by placing free-hand regions of inter-
est around the pale areas on TTC sections, using
image analysis freeware (ImageJ 1.37 for Macintosh;
NIH, Bethesda, Maryland, USA), with the investiga-
tor blinded to the identities of the sections.
Statistical methods
Data analysis was software-assisted, using Prism
version 4.03 (Graph Pad Inc., San Diego, CA).
Parametric data are expressed as mean ± SD and
non-parametric data as mean (range) unless otherwise
stated. Differences between groups were tested for
statistical signiﬁcance using unpaired t test or Mann-
Whitney U test for parametric and non-parametric
data, respectively.
Results
General ﬁndings
A total of 42 rats were successfully subjected to
MCAO; 23 rats were excluded due to either subarach-
noid hemorrhage (SAH) on post-mortem examination
(control=5,S-PBN=3)orpostoperativemortalitynot
attributed to SAH (control = 8, S-PBN = 7). Another
6 rats were excluded due to unacceptable arterial
blood gases (control = 2, S-PBN = 4). The resulting
13 rats were included for analysis of infarct size and
neurological tests (control = 7, S-PBN = 6). All
included rats showed signs of EEG signal depression
consistent with adequate ﬁlament placement approx-
imately 3–5 min after MCAO. Physiological data are
shown in Table I.
Neurological testing
All included rats showed contralateral motor deﬁcit
at recovery from anesthesia, indicating successful
MCAO. After 1 day of survival the S-PBN-treated
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(1 (1–3) versus 3 (2–3); P < 0.05) according to the
scoring described by Bederson et al. (16) (Figure 1).
The performance on the inclined plane was similar at
base-line but better in the S-PBN-treated rats than
controls after 1 day of survival, both in terms of
absolute (74.5 ± 4.6% versus 66 ± 8.3%; P < 0.05)
andrelativechanges (1.7 ± 2.8% versus9.0 ± 3.3%;
P < 0.01) (Figure 2).
Infarct size
All included rats showed pallor anatomically corre-
sponding to the MCA territory leaving normal tissue
red after TTC staining (Figure 3). Integrating the
areas in 2-mm slices for volumetric assessment
revealed similar total brain (1054 ± 61 mm
3 versus
1102 ± 86 mm
3; NS) and infarct (206 ± 18 mm
3
versus 213 ± 57 mm
3; NS) volumes in the S-PBN-
treated and the control rats.
Table I. Physiological data: pH, arterial pO2, pCO2, base excess
(BE), blood glucose (B-glucose 0 = at middle cerebral artery
occlusion (MCAO); B-glucose 120 = MCAO + 120 min), blood
pressure (BP), body temperature (Temp = temperature at MCAO),
body weight, volume of saline substitution perioperatively. Data are
shown as mean ± SD. There were no statistically signiﬁcant dif-
ferences between the groups.
S-PBN Controls
pH 7.40 ± 0.02 7.38 ± 0.03
pO2 (kPa) 10.3 ± 1.0 10.2 ± 0.9
pCO2 (kPa) 5.7 ± 0.3 6.0 ± 0.3
BE (mmol/L) 2.2 ± 1.3 2.5 ± 3.1
B-glucose 0 (mmol/L) 13.7 ± 2.9 14.7 ± 3.2
B-glucose 120 (mmol/L) 12.2 ± 1.6 11.1 ± 1.4
BP (mmHg) 105 ± 15 107 ± 7
Temp (C) 37.5 ± 0.4 37.4 ± 0.4
Saline volume (mL) 21.3 ± 1.5 22.8 ± 1.6
Body weight (g) 279 ± 29 305 ± 69
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Figure 1. Neurological scoring according to Bederson et al. (16)
(ranging from: 0 = normal, 1 = forelimb ﬂexion, 2 = decreased
resistance to lateral push, or 3 = circling) indicated a better per-
formance in the S-PBN-treated group than in the control group.
*P <0.05(Mann-Whitneytest) (S-PBN= sodium 2-sulfophenyl-N-
tert-butyl nitrone).
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Figure 2. Performance on the inclined plane. The average of the
three maximal angles was recorded prior to middle cerebral artery
occlusion (MCAO) and after 1 day of survival. The S-PBN group
managed better than the controls. Mean ± SD for 6 S-PBN-treated
and 7 control rats. *P < 0.05; **P < 0.01 (unpaired t test)
(S-PBN = sodium 2-sulfophenyl-N-tert-butyl nitrone).
S-PBN
Control
Figure 3. Volumetric analyses of the total brain volume and infarct
size were carried out in serial 2 mm slices of brain tissue stained by
tetrazolium red (TTC). Normal tissue is stained by TTC while the
infarcts appear pale.
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The present results indicate that S-PBN may amelio-
rate hyperglycemic-ischemic brain damage by other
mechanisms than reducing the infarct size, since only
neurological performance was improved after 1 day
of survival. During normoglycemia, non-sulfonated
PBN reduced the infarct size by approximately 30%
(18) as compared with 70% in hyperglycemic-
ischemic injury (2). In our study, S-PBN improved
the neurological performance but did not reduce
infarct sizes, which contrasts to the more coherent
data reported for PBN (8). Moreover, there was no
correlation between infarct size and performance on
the inclined plane (detailed data not shown). Possibly,
structural differences between PBN and S-PBN might
exert effects on, for instance, cerebral glucose metab-
olism (19) that might contribute to this discrepancy.
Under physiological conditions, glucose is the main
substrate for cerebral adenosine triphospate (ATP)
production and glycogen deposition (20). Normal
brain function requires continuous delivery of glucose
and oxygen; and the relationship between cerebral
blood ﬂow (CBF) and glucose metabolism is tightly
controlled (21). The brain is to some extent capable of
adapting to different glucose levels by regulation of
glucose transport and metabolism; however, these
mechanisms probably apply to chronic changes
such as diabetes mellitus or repeated hypoglycemic
events rather than acute ischemia (20).
In the present study, the induced hyperglycemia
was well above the levels associated with poor stroke
outcome (3,4). In line with this observation, the
mortality not attributed to SAH was high among
rats with successful MCAO. Interestingly, a post-hoc
analysis of the survivors and non-survivors revealed
that the only discrepant parameter between these two
groups was the blood glucose level at MCAO and
after 120 min. The values in the non-survivor group
were 2.3 mmol/L and 3.6 mmol/L higher, respec-
tively, at these two time points (data not shown). In
cerebral ischemia, hyperglycemia accelerates the
ischemic brain damage, which supposedly occurs
through various mechanisms such as oxidative stress,
increased acidosis, mitochondrial and microvascular
dysfunction, and increased inﬂammation (22). Recent
reviews have focused on oxidative stress to explain
the hyperglycemic-ischemic damage, and four main
mechanisms have been identiﬁed. These are protein
kinase C (PKC) activation, advanced glycation end-
products (AGE), increased aldose reductase and hex-
osamine pathway ﬂuxes. All of these mechanisms are
associatedwith increased superoxide formation, which
has been pointed out as the major source of oxidative
stress in hyperglycemia (23).
Oxidative stress, mainly in terms of RONS, has
received considerable attention in the efforts to
understand the pathology of cerebral ischemia. The
superoxide sources include arachidonic acid as well as
xanthine oxidase metabolism and disturbed mito-
chondrial function (24). Furthermore, nitric oxide
(NO), being a substrate for reactive compounds
(24), increases in different phases of cerebral ische-
mia, probably as a result of the dynamic activity
patterns of different neuronal and endothelial nitric
oxide synthase (NOS) activities (25). Both hypergly-
cemia and ischemia separately result in increased
loads of superoxide and NO, compounds that may
be injurious per se or perhaps even more so by
contributing to enhanced formation of peroxynitrite.
The latter mechanism has been advocated recently
in a thorough review of this ﬁeld (26). It is also
conceivable that hyperglycemia-induced, RONS-
dependent impaired endothelial function (27) may
further contribute to the ischemic process of the
vasculature and the corresponding territories. Inter-
estingly, hyperglycemia-induced depletion of endo-
thelium and vascular muscle of nicotinamide adenine
dinucleotide phosphate (NADPH) leads to reduced
intracellular antioxidant capacity (28), which might in
turn render the tissue vulnerable to RONS damage.
The estimated burst-like increase of RONS is
approximately 4-fold upon early reperfusion after
cerebral ischemia (28), and in the present study
S-PBN was given primarily in order to cover this
time window of anticipated RONS provocation.
The neuroprotective action of the non-sulfonated
PBN is incompletely known, but possibly interferes
with inﬂammation (29) and penumbral microcircu-
lation by promoting the recovery of metabolism (7).
S-PBN is less characterized, but appears to share the
spin-trapping effects of PBN in vitro (30). S-PBN has
higher polarity and plasma clearance than PBN, and
after experimental traumatic brain injury (TBI) the
S-PBN penetration of the blood brain barrier (BBB)
has been negated (10). Nevertheless, the beneﬁcial
effects after TBI were comparable between S-PBN
and PBN regarding functional and morphological
outcome (19). The explanation for this is unclear
but might possibly relate to improved vascular func-
tion in the affected brain regions. Recently, S-PBN
has been shown to modulate the immune cell traf-
ﬁcking over the BBB following TBI (31), a phenom-
enon in support of the notion that S-PBN affects
vascular function.
The Stroke Acute Ischemic NXY-059 Study
(SAINT) demonstrated that the S-PBN-related
compound NXY-059 improved outcome after
acute ischemic stroke (32), but disappointingly the
subsequent SAINT II trial did not conﬁrm these
166 M. Molnar & F. Lennmyrresults (12). Methodological concerns regarding
nitrone decomposition (33) might be of relevance
in interpreting these discrepant ﬁndings, and in addi-
tion other shortcomings of these studies have been
pointed out (34). In the case of ischemic stroke with
concomitant hyperglycemia, the SAINT trials are
most likely underpowered to exclude any beneﬁcial
effects of NXY-059. Thus together with the experi-
mental support of nitrones we consider combined
hyperglycemia and cerebral ischemia as an interesting
target for experimental and clinical studies also in the
future.
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